摘要
目的:探讨雷尼替丁对服用奥氮平治疗精神分裂症患者糖、脂代谢水平及体质量的影响。方法:选取2014年4月—2015年2月广州市民政局精神病院收治的120例精神分裂症患者作为研究对象,按随机数字表法分为观察组和对照组各60例。观察组患者给予口服奥氮平及雷尼替丁,对照组给予口服奥氮平及安慰剂。随访24周,观察患者治疗前、后体质量,血糖及血脂的变化,比较疗效及不良反应。结果:治疗12、24周后,对照组患者空腹血糖(FPG)、血清三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)分别为(8.11±1.63)、(4.96±0.74)、(1.81±0.67)、(2.71±1.01)mmol/L和(9.34±1.93)、(5.49±0.98)、(2.59±0.72)、(3.34±1.06)mmol/L,与治疗前的(6.71±1.42)、(4.54±0.39)、(1.34±0.54)、(2.17±0.42)mmol/L比较,差异均有统计学意义(P<0.05)。治疗12、24周后,观察组患者FPG、TC、TG、高密度脂蛋白胆固醇(HDL-C)、LDL-C分别为(6.92±1.41)、(4.71±0.52)、(1.41±0.43)、(1.42±0.53)、(2.27±0.52)mmol/L和(7.12±1.63)、(4.82±0.55)、(1.52±0.46)、(1.46±0.54)、(2.38±0.64)mmol/L,均高于治疗前的(6.67±1.38)、(4.67±0.41)、(1.32±0.37)、(1.38±0.40)、(2.11±0.35)mmol/L,差异无统计学意义(P>0.05)。治疗12、24周后,对照组患者腰围、体质量、体质量指数均较治疗前明显升高,差异有统计学意义(P<0.05);观察组患者腰围、体质量、体质量指数稍高于治疗前,差异无统计学意义(P>0.05)。对照组患者的总有效率为80.00%(48/50),观察组为83.33%(50/60),2组的差异无统计学意义(P>0.05);对照组患者不良反应发生率为21.67%(13/60),观察组为25.00%(15/60),2组的差异无统计学意义(P>0.05)。结论:雷尼替丁可明显控制精神分裂症患者糖、脂代谢水平,避免患者体质量增加,效果较好且用药安全,值得临床推广。
OBJECTIVE：To probe into the effects of ranitidine on the glucose and lipid metabolism level and body mass of patients with olanzapine in treatment of schizophrenia.METHODS：120 patients with schizophrenia admitted into Guangzhou Civil Affairs Bureau Psychiatric Hospital from Apr.2014 to Feb.,2015 were selected to be divided into observation group and control group via the random number table,with 60 cases in each.The observation group were treated with oral olanzapine and ranitidine while the control group received oral olanzapine and placebo.Followed up for 24 weeks,the changes of body mass,blood glucose and blood lipid before and after treatment were observed;the efficacy and adverse reactions in two groups were compared.RESULTS：After treatment of 12 weeks,in control group,the fasting blood glucose（FBG）,triglycerides（TG）,total cholesterol（TC） and low density lipoprotein（LDL-C）were respectively（8.11 ± 1.63） mmol / L,（4.96 ± 0.74） mmol / L,（1.81 ± 0.67） mmol / L and（2.71 ± 1.01） mmol / L,after treatment of 24 weeks,the data were respectively（9.34 ± 1.93） mmol / L,（5.49 ± 0.98） mmol / L,（2.59 ± 0.72）mmol / L and（3.34 ± 1.06） mmol / L,compared with before treatment（6.71 ± 1.42） mmol / L,（4.54 ± 0.39） mmol / L,（1.34 ± 0.54） mmol/L and（2.17 ± 0.42） mmol/L,the difference was statistically significant（P 〉0.05）.After treatment of 12 weeks,in observation group,the FBG,TC,TG,HDL-C and LDL-C were respectively（6.92 ± 1.41）mmol / L,（4.71 ± 0.52） mmol / L,（1.41 ± 0.43） mmol / L,（1.42 ± 0.53） mmol / L and（2.27 ± 0.52） mmol / L;and aftertreatment of 24 weeks,the data was（7.12 ± 1.63） mmol / L,（4.82 ± 0.55） mmol / L,（1.52 ± 0.46） mmol / L,（1.46 ± 0.54）mmol / L and（2.38 ± 0.64） mmol / L,significantly higher than that of before treatment（6.67 ± 1.38） mmol / L,（4.67 ± 0.41） mmol/L,（1.32 ± 0.37） mmol/L,（1.38 ± 0.40） mmol/L and（2.11 ± 0.35） mmol/L,the difference was not statistically significant（P〉 0.05）.After treatment of 12 and 24 weeks,the waist,body mass and body mass indicators of control group increased significantly compared with before treatment,with statistical significance（P〈 0.05）;while in observation group,the data were slightly higher than those before treatment,the difference was not statistically significant（P 〉0.05）.The total effective rate of control group was 80.00%（48 /50）,and observation group was 83.33%（50 /60）,the difference was not statistically significant（P 〉0.05）.The incidence of adverse drug reactions in control group was 21.67%（13 /60）,and in observation group was 25.00%（15 /60）,the difference was not statistically significant（P 〉0.05）.CONCLUSIONS：Ranitidine can effectively control the glucose and lipid metabolism level of patients with schizophrenia,avoid the abnormal increase of body mass;meanwhile,the effects are remarkable with safe medication.It is worthy of clinical application and promotion.
出处
《中国医院用药评价与分析》
2016年第4期433-436,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
2014年梅州市科技计划项目(No.2014B35)
关键词
雷尼替丁
奥氮平
精神分裂症
糖脂代谢水平
体质量
Ranitidine
Olanzapine
Schizophrenia
Glucose and lipid metabolism level
Body mas
